Cardio Diagnostics Holdings, Inc.
CDIOAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Benchmark | maintain | Speculative Buy | Aug 27, 2024 |
| Benchmark | maintain | Speculative Buy | Jun 6, 2024 |
| Benchmark | maintain | Speculative Buy | Apr 19, 2024 |
| Benchmark | maintain | Speculative Buy | Jun 15, 2023 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.59 | — | $3.6K | — |
| Aug 7, 2026 | $-0.51 | — | $5.4K | — |
| May 15, 2026 | $-0.63 | — | $2.7K | — |
| Mar 13, 2026 | $-0.80 | $-1.80 | $3.6K | $250.0K |
| Nov 12, 2025 | $-0.98 | $-1.80 | $2.9K | $150.0K |
| Aug 14, 2025 | $-0.97 | $-1.80 | $7.5K | $75.0K |
| May 15, 2025 | $-0.97 | $-1.80 | $940.00 | $50.0K |
| Apr 1, 2025 | $-0.06 | $-0.16 | $25.0K | $25.0K |
News
Genmab A/S (NASDAQ: GMAB - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings. Volatility and Risk Genmab A/S has a beta
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO - Get Free Report) was the target of a large drop in short interest in September. As of September 15th, there was short interest totaling 5,259 shares, a drop of 77.7% from the August 31st total of 23,626 shares. Currently, 0.2% of the shares of the stock are short sold.
Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript
Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Profitability This table compares Sutro Biopharma and
[url="]Cardio Diagnostics Holdings, Inc.[/url] (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edit
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has released a new edition of the company's rural health report: The State of Rural Hospitals and Cardiovascular Care.
Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.